CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 47.2% in December

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 25,600 shares, an increase of 47.2% from the November 30th total of 17,390 shares. Based on an average daily volume of 13,432 shares, the days-to-cover ratio is presently 1.9 days. Approximately 4.1% of the shares of the company are short sold. Approximately 4.1% of the shares of the company are short sold. Based on an average daily volume of 13,432 shares, the days-to-cover ratio is presently 1.9 days.

Institutional Investors Weigh In On CNS Pharmaceuticals

An institutional investor recently bought a new position in CNS Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 406,000 shares of the company’s stock, valued at approximately $335,000. Armistice Capital LLC owned approximately 90.22% of CNS Pharmaceuticals as of its most recent SEC filing. 14.02% of the stock is owned by hedge funds and other institutional investors.

CNS Pharmaceuticals Price Performance

NASDAQ:CNSP traded up $0.01 during mid-day trading on Monday, hitting $6.21. 787 shares of the company’s stock were exchanged, compared to its average volume of 67,555. The company has a market cap of $3.85 million, a PE ratio of -0.20 and a beta of 2.62. CNS Pharmaceuticals has a one year low of $4.93 and a one year high of $114.00. The business has a fifty day moving average price of $7.07 and a 200 day moving average price of $8.00.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its earnings results on Friday, November 14th. The company reported ($5.76) EPS for the quarter, topping the consensus estimate of ($6.63) by $0.87.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen downgraded CNS Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 5th. Finally, Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CNS Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.